| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8651102 | American Heart Journal | 2018 | 27 Pages |
Abstract
The effect of more potent P2Y12 inhibitors compared with clopidogrel on efficacy and safety end points is consistent in elderly and younger patients. These data imply that potent P2Y12 inhibitors should not be withheld from eligible patients solely because of advanced age.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Giuseppe MD, PhD, FESC, Daisuke MD, PhD, Gianpiero MD, Giulia MD, Giuseppe MD, Gregg W. MD, Sorin J. MD,